Order supports customer’s full launch, with shipments expected to commence shortly and be fulfilled over 12 -15 months ...
Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide ...
LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today ...
NAMSA, the global leader in MedTech contract research offering end-to-end development services, today announced a strategic ...
On the sidelines of the initiative's launch, Pharco signed a cooperation protocol with the Egyptian Ophthalmological Society ...
14d
LTS Lohmann Therapie-Systeme AG: LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today ...
Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive ...
Garden City University has broken ground for the Ashanti region’s first private University teaching hospital. The 100-bed ...
On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026Well-capitalized with $106.9 million in ...
Ladies and gentlemen, thank you for standing by, and welcome to Aptar's 2026 First Quarter Results Conference Call. [Operator Instructions] Introducing today's conference call is Mrs. Mary Skafidas, ...
Q1 2026 Earnings Call May 6, 2026 8:00 AM EDTCompany ParticipantsPaul Josephs - President, CEO & DirectorRyan Lake ...
AptarGroup's elastomeric components for injectable medications posted exceptional growth in the first quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results